- 1
- 2

Bionow
Bionow is with the UK delegation at booth #30
Bionow is a not for profit membership organisation supporting the biomedical, pharma and life sciences sectors across the North of England. Bionow does this by bringing people together at our exciting conferences and events across the North, being an advocate for the North, and providing comprehensive procurement member benefits that strengthen the competitiveness of the North’s innovative life science sector.
Our mission is to provide the tools and support for your organisation to become amongst the most competitive in the industry through our range of specialist products and services.
Mr David Holmes
Membership Manager
BioPartner UK
Lin Bateson
Chief ExecutiveChris Tena
Team AdministratorWiki Molodziejko
Marketing Executive
Kuano
Our team combines drug discovery specialists with physicists, chemists and computer scientists committed to use cutting-edge technologies to make a difference to people’s lives.
We are supported by an expert team of advisors that are working closely with us on corporate and business development, as well as, ongoing scientific development of our proprietary modelling and AI technology.
Catherine Stace
VP Business Development
MediWales
MediWales is with the UK delegation at booth #30
MediWales is an independent and not-for-profit network that connects industry, academia and the clinical community in Wales to support the advancement of human life science. It offers membership, events, publications and collaboration opportunities for its members and the sector.
Ms Debbie Laubach
Operations Manager
National Institute for Health and Care Research (NIHR)
Exhibiting at booth #33
The NIHR works in partnership with the life sciences industry and CROs to design and deliver research within the UK health and social care environment to generate clinical evidence.
From early-stage, translational research through to late-stage clinical trials, a full range of free support is available. We offer:
Access to world-leading academic and clinical expertise, collaborations and partnerships.
Support to rapidly determine if your study is compatible with UK clinical practice.
Help to effectively and efficiently plan, place and deliver your research.
Support in accessing funding, health data and clinical samples.
Help to engage patients to improve your study design and optimise recruitment and retention.
Assistance to help you navigate the UK health and research system.
Ms Sophie Middleton
Events and Marketing AssistantMs Tanya Turgoose
Business Development ManagerMr Nirmal Perera
Senior Business Development ManagerMiss Alicia Cox
Senior Business Development ManagerMr Hyder Latif
Business Development ManagerMs Emanuela Mariani
Business Development Manager
New Anglia LEP
Exhibiting with the UK delegation at booth #30
The Norfolk and Suffolk region offers a supportive ecosystem for investors and businesses with access to talent, funding, infrastructure, markets, networks, events and more. Norfolk and Suffolk Unlimited can facilitate introductions, collaborations, and partnerships with key stakeholders across industry, academia, and government.
Let’s discuss how we can help your organisation thrive in our region.
Ms Alice Tomkins
Economic Development OfficerMs Joanne Kerrison
Inward Investment Manager
Onyx Scientific
Exhibiting with the UK delegation at booth #30
Onyx Scientific is the CDMO division of Ipca Laboratories, offering small molecule drug substance development and manufacturing services. Our MHRA-licensed sites in the UK offer early development of candidate APIs and manufacturing for clinical phases through to commercial supply. Dedicated solid-state and analytical chemistry teams expedite development activities at Onyx but are also available to provide full-service outsourced projects to complement or support your in-house campaigns. With a wealth of early development experience and success, our pragmatic, fit-for-purpose approach focuses on rapid process development and a view to future GMP campaigns. Where required, scale-up through Phase II towards commercial manufacture is retained either at our UK site or within the Group through transfer to our sister sites and colleagues in the USA and India.
Dr Chris Atherton
Commercial ManagerDr Julian Northen
Solid State Manager
Pracipio
Pracipio is with the UK delegation at booth #30
Anticipate, advise and advance - Pracipio helps you achieve your business objectives by applying a team of consultants who have formed a best in class management and strategy consultancy.
Mr Fredrik Elg
DirectorRoslin Cell Therapies Limited
Exhibiting with the UK delegation at booth #30
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and manufacturing the first-ever US FDA-approved CRISPR-based gene therapy CASGEVY™. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
Mr Andy Paterson
Senior Business Development Manager
SGS Quay Pharma
Exhibiting with the UK delegation at booth #30
WORLD-LEADING INNOVATIVE FORMULATION CDMO
We are a Contract Development Manufacturing Organisation (CDMO). We specialise in the development of innovative new entities for biotech companies, globally.